Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.43 USD | +2.93% | +3.18% | +6.98% |
Sales 2024 * | 204K 278K | Sales 2025 * | 11.85M 16.2M | Capitalization | 188M 257M |
---|---|---|---|---|---|
Net income 2024 * | -72M -98.42M | Net income 2025 * | -62M -84.75M | EV / Sales 2024 * | 923 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 15.9 x |
P/E ratio 2024 * |
-2.53
x | P/E ratio 2025 * |
-3.62
x | Employees | 24 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.15% |
Latest transcript on Outlook Therapeutics, Inc.
1 day | +2.93% | ||
1 week | +3.18% | ||
Current month | -29.40% | ||
1 month | -2.88% | ||
3 months | -2.43% | ||
6 months | -21.07% | ||
Current year | +6.98% |
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +6.26% | - | |
0.00% | 147 M€ | +4.88% | - | |
0.00% | 18 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 8.43 | +2.93% | 120,913 |
24-04-25 | 8.19 | -0.12% | 150,771 |
24-04-24 | 8.2 | 0.00% | 339,980 |
24-04-23 | 8.2 | +1.36% | 151,657 |
24-04-22 | 8.09 | -0.98% | 210,765 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.98% | 188M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- OTLK Stock